Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Stellanova Therapeutics

Request full access

Developing the first cancer therapies targeting cancer-associated fibroblasts (CAFs) and their symbiotic interactions within the tumor microenvironment

Houston, United States

About Stellanova Therapeutics

Stellanova Therapeutics, established in 2019, is a Houston-based biotechnology firm operating in the oncology sector. The company was co-founded by Dr. Rosa Hwang, Ronald DePinho, and Emmanuelle Schuler, who also serves as the founding CEO. Stellanova's inception is rooted in the research from Dr. Hwang's lab at MD Anderson Cancer Center. The company's scientific focus is on developing therapies that target the tumor microenvironment, a departure from traditional approaches that focus solely on cancer cells.

The core of Stellanova's strategy is to counteract the pro-tumorigenic effects of carcinoma-associated fibroblasts (CAFs). These cells are known to play a significant role in promoting cancer growth, metastasis, and resistance to therapy. The business operates on a preclinical development model, aiming to advance its discoveries into clinical trials. Its primary client base would eventually be patients with advanced cancers, though its immediate stakeholders are partners in the pharmaceutical and biotech industries. Revenue generation will be contingent on the successful development and commercialization of its therapeutic candidates, likely through partnerships, licensing deals, or acquisition.

Stellanova's lead product candidate is an antibody designed to neutralize DKK3, a factor secreted by CAFs that promotes tumor progression and therapy resistance. This antibody has demonstrated robust anti-tumor activity in preclinical models of treatment-resistant pancreatic and triple-negative breast cancers, particularly when used in conjunction with immune checkpoint inhibitors. The company's platform integrates advanced computational biology and genetic engineering to identify and validate novel targets within the tumor microenvironment. A significant milestone was achieved on June 3, 2021, when Stellanova secured $15.5 million in a Series A financing round led by Sporos Bioventures. This funding was earmarked to advance the lead antibody into first-in-human clinical trials, expand its discovery platform, and grow the team. The company was a resident at JLABS @ TMC, a Johnson & Johnson biotech incubator, and was later acquired by Sporos Bioventures.

Source: Dealroom company data

At a glance

Status
Operational
Headquarters
Houston, United States
Employees
1
Open positions
None listed
Dealroom signal
4.8/100

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jun 2021 $16M $62M Sporos Bioventures —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Stellanova Therapeutics website traffic

Latest recorded traffic for Stellanova Therapeutics is 250 monthly website visits, up 108.3% over the last three months. Stellanova Therapeutics's team declined 80% over the past year.

Latest monthly visits250 3-month web change+108.3% 1-year team growth-80%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Stellanova Therapeutics in the Houston ecosystem

Live from Dealroom

The Stellanova Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Sporos Bioventures
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Stellanova Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Stellanova Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.